Jubilant Pharmova Ltd
BSE: 530019
values in crores
Revenue & Profit Trend
in croresRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|---|---|---|
| INCOME | |||||||
| Revenue | 70.30+4.5% | 67.30+1.4% | 66.40+11.6% | 59.50-72.6% | 217.30+10.9% | 196.00+18.3% | 165.70 |
| Other Income | 0.50+25.0% | 0.40-50.0% | 0.80+14.3% | 0.70-96.1% | 17.90-2.7% | 18.40-58.0% | 43.80 |
| Total Income | 70.80+4.6% | 67.70+0.7% | 67.20+11.6% | 60.20-74.4% | 235.20+9.7% | 214.40+2.3% | 209.50 |
| EXPENSES | |||||||
| Expenditure | 58.00+0.7% | 57.60-1.9% | 58.70+9.3% | 53.70-74.6% | 211.70+2.9% | 205.70+6.6% | 192.90 |
| Tax | -53.10-1617.1% | 3.50-93.8% | 56.50+2254.2% | 2.40-75.8% | 9.90+191.2% | 3.40-44.3% | 6.10 |
| PROFIT | |||||||
| PBT | 4.10-59.4% | 10.10+18.8% | 8.50+30.8% | 6.50-72.3% | 23.50+170.1% | 8.70-47.6% | 16.60 |
| Net Profit | 57.20+766.7% | 6.60+203.1% | -6.40-210.3% | 5.80-57.4% | 13.60+156.6% | 5.30-49.5% | 10.50 |
| KEY METRICS | |||||||
| OPM % | 8.25%-9.88pp | 18.13%+0.36pp | 17.77%+0.46pp | 17.31%+5.34pp | 11.97%+27.48pp | -15.51%+13.64pp | -29.15% |
| NPM % | 80.79%+71.04pp | 9.75%+19.27pp | -9.52%-19.15pp | 9.63%+3.85pp | 5.78%+3.31pp | 2.47%-2.54pp | 5.01% |
| EPS | 3.59+754.8% | 0.42-86.1% | 3.02+1061.5% | 0.26-69.8% | 0.86+160.6% | 0.33-50.0% | 0.66 |
Corporate Events
Board MeetingJUBLPHARMA
202419Jul
Board Meeting
Inter-alia consider and approve Unaudited Standalone and Con…
BSE Filing ↗ Board MeetingJUBLPHARMA
202429May
Board Meeting
Consider and approve Audited Standalone and Consolidated Fin…
BSE Filing ↗ Board MeetingJUBLPHARMA
20242Feb
Board Meeting
Consideration and approval of Board Meeting Intimation for u…
BSE Filing ↗ Board MeetingJUBLPHARMA
202327Oct
Board Meeting
Consider and approve Unaudited Standalone and Consolidated F…
BSE Filing ↗